Cancer Treatment Reviews

Article	Citations
Editorial Board	250
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	235
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty	233
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	175
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	157
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	146
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming	126
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	111
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	94
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	86
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	84
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	83
Editorial Board	82
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era	81
Emerging antibody-based therapies for the treatment of acute myeloid leukemia	77
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	75
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features	70
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	67
Optimizing care in early phase cancer trials: The role of palliative care	66
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	64
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	64
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment	63
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis	61
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma	61
If it’s a target, it’s a pan-cancer target: Tissue is not the issue	58

De-escalation strategies with targeted therapies in non-small cell lung cancer	58
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications	58
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	54
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	52
Editorial Board	50
Uncertainties and controversies in axillary management of patients with breast cancer	49
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy	48
Editorial Board	48
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation	48
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	46
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	46
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	45
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	45
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	45
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis	44
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?	44
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]	44
Extracellular vesicles and the “six Rs” in radiotherapy	44
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier	43
The immunogram of inflammatory breast cancer	42
Editorial Board	42
Overview of BH3 mimetics in ovarian cancer	42
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review	42
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design	41
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review	40
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis	40
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada	39
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features	38
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside	38
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma	37
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)	36
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives	36
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities	36
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma	36
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers	36
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies	35
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review	35
Editorial Board	35
Long-term surveillance recommendations for young adult cancer survivors	35
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer	35
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies	34
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review	34
Agnostic drug development revisited	34
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer	32
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life	32
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis	32
Systematic review of the CUP trials characteristics and perspectives for next-generation studies	31
Bone complications of cancer treatment	31
Malignant ascites: Current therapy options and treatment prospects	31
Immunocytokines in cancer treatment: A systematic review	30

Editorial Board	30
Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review	30
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers	30
Acknowledgement to Reviewers 2021	28
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review	28
Editorial Board	28
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review	28
Genomic distinctions in adolescent and young adult cancer: A comprehensive review	27
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?	27
Local control strategies for management of NSCLC with oligoprogressive disease	27
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?	27
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review	27
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review	26
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review	26
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification	26
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes	25
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	25
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]	25
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications	25
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis	24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives	24
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis	24
Review: Targeting EZH2 in neuroblastoma	24
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies	24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project	24
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie	24
Engineering strategies to optimise adoptive cell therapy in ovarian cancer	24
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]	23
Pharmacotherapy for leptomeningeal disease in breast cancer	23
Strategies for improving detection of circulating tumor DNA using next generation sequencing	23
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis	23
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence	23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	23
Evolving immunotherapeutic solutions for triple-negative breast carcinoma	23
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression	22
SELNET clinical practice guidelines for soft tissue sarcoma and GIST	22
Editorial Board	22
Editorial Board	22
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review	21
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies	21
Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis	21
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis	21
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review	21
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications	21
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives	20
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases	20
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]	20
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis	20
Clinical overview of trophoblast surface antigen 2 Antibody-Drug conjugates in Non–Small cell lung cancer	20
Editorial Board	20
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis	20
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy	20
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment	20
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma	20
Editorial Board	20
An umbrella review of systematic reviews on the diagnostic and prognostic utility of circulating tumor DNA and MicroRNA in colorectal cancer	19
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	19
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments	19
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives	19
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans	19
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas	19
A systematic review of eHealth technologies for breast cancer supportive care	19
Multimodality treatment of primary cardiac angiosarcoma: A systematic literature review	19
Editorial Board	19
Advances in treatment strategies for low-grade serous ovarian cancer	19
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia	18
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group	18
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy	18
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action	18
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer	18
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma	17
Clinical course and treatment outcomes in solid-basaloid adenoid cystic carcinoma of the breast: A systematic review and case report	17
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?	17
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis	17
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)	17
Clearer Horizons: The latest advances in clear cell ovarian cancer treatment	16
Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350]	16
Corrigendum to “PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives” [Cancer Treat. Rev. 131 (2024) 102850]	16
Local administration of immunotherapy for patients with skin cancer: A systematic review	16

Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy	16
Exercise in patients with metastatic prostate cancer: A comprehensive review	16
Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist	16
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?	15
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer	15
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives	15
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives	15
Germline TP53 pathogenic variants and breast cancer: A narrative review	15
CAR-T cell therapy for breast cancer: Current status and future perspective	15
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice	14
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis	14
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck	14
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians	14
T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis	14
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review	14
Current controversies in the use of Oncotype DX in early breast cancer	14
Editorial Board	14
Editorial Board	13
Editorial Board	13
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management	13
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment	13
Acquired resistance mechanisms to osimertinib: The constant battle	13
Editorial Board	13
Editorial Board	13
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations	12
Chimeric antigen receptor NK cells for breast cancer immunotherapy	12
The current clinical landscape of personalized cancer vaccines	12
Editorial Board	12
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer	12
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer	12
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing	12
Systematic review of fetal and placental metastases among pregnant patients with cancer	12
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?	12
Antibody based therapies in Hodgkin lymphoma	12
Molecular aspects of brain metastases in breast cancer	12
Beyond HER2: Targeting the ErbB receptor family in breast cancer	12
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer	12
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group	12
Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives	12
Editorial Board	12
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer	12
Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into ac	11
Editorial Board	11
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	11
Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses	11
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development	11
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma	11
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review	10
Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis	10
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors	10
Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review	10
Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck	10
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies	10
Editorial Board	10
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges	10
Editorial Board	10
Long road towards effective HER3 targeting in breast cancer	10
Immunotherapy-based combinations in metastatic NSCLC	10
Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment	10
Bone metastases in NSCLC: Modern paradigms in management and supportive care	10
Corrigendum to “Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis” [Cancer Treat. Rev. 125 (2024) 102704]	10
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours	10
Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials	9
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers	9
Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials	9
Editorial Board	9
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma	9
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation	9
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis	9
Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review	9
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review	9
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States	9
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists	9
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy	8
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective	8
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer	8
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review	8
NTRK gene fusion testing and management in lung cancer	8
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome	8
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma	8
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer	8
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	8
Toxicities following CAR-T therapy for hematological malignancies	8
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	8
Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer	8
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev.	8
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers	8
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer	8
Editorial Board	8
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic r	8
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives	7
Locally advanced and metastatic endometrial cancer: Current and emerging therapies	7
Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: A systematic review and meta-analysis	7
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives	7
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration	7